![](/img/cover-not-exists.png)
Concerns about data reporting and interpretation in “Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial”
David M. Marks, Jonathan S. Abramowitz, Glen I. SpielmansVolume:
46
Year:
2012
Language:
english
Pages:
2
DOI:
10.1016/j.jpsychires.2012.02.002
File:
PDF, 84 KB
english, 2012